8:25 am Chair’s Opening Remarks

8:30 am The Landscape of Bi/Multispecifics


  • Drawing comparison between cell engager and immune checkpoint modulator targeted bi/multispecifics
  • Discussing the fourth wave of drug- multispecifics landscape
  • Analyzing emerging trends in the multispecific therapies

Uncovering the Multispecifics Landscape for a Holistic Overview

9:00 am Session Reserved for BSP

9:10 am Panel Discussion – CAR T vs. Multispecifics


  • Uncovering the dual Targeting of CAR-T & How Multispecifics Differ
  • Discussing the most pressing challenges facing CAR-TCR and Multispecific fields
  • Sharing thoughts on how to drive the cell therapy field into a new era of more accessible ‘curative’ therapies

9:45 am
Speed Networking


This session is the ideal opportunity to take advantage of informal networking time and understand who is also prioritizing and overcoming challenges within the various sectors of the multispecifics world

10:15 am
Morning Break

Target Discovery, Mechanistic Diversity & Translational Science

Target Discovery

10:45 am On and Off-Target Toxicities of Bispecific Targeted Biologics: Mitigation Strategies

  • Rakesh Dixit President and Head of R&D, Co-Founder, Regio Biosciences


  • Measuring affinity for each bi or multispecific molecule as these cells can get activated very quickly
  • Understanding the cause of a more generalized immune activation response
  • Rationalizing routes for on/off-target selection and understanding the requirements for T cell activation

11:15 am Early Developability of Multispecifics

  • Vera Sellers Associate Director - Molecule Group, Protein & Cell Sciences Discovery & Development Technologies, EMD Serono


  • Exploring an array of targets, and taking creative scientific approaches to developing novel therapies
  • Critically evaluating new molecules and using developability and stability to ensure that these molecules can progress through the pipeline

11:45 am Session Reserved for AlivaMab Discovery


Novel Formats, Product Design & Manufacturability

Novel Formats

10:45 am Engineering Safe & Effective Bispecific Immunotherapies for Solid Tumor Indications

  • Shaun Lippow Vice President, Drug Discovery & Protein Engineering, Atreca


  • Developing 4-1BB bispecifics with tumor-targeting for enhanced therapeutic window
  • Optimizing CD3 bispecifics to novel tumor targets and epitopes

11:15 am Target Biology & Antibody Attributes Drive Multispecific Format Selection & Engineering


  • Screening to identify “binding modules” for use in multispecifics results in antibodies with many attributes
  • These attributes can guide selection of specific multispecific formats
  • Using an agonist target as a case study, this presentation will aim to describe format selection and
    engineering to optimize agonist activity

11:45 am Session Reserved for OmniAb


12:15 pm
Lunch & Networking

Mechanistic Diversity

1:15 pm CLEC5a-Directed Bispecific Antibody for Effective Cellular Phagocytosis


  • Activating Fcγ receptor is a key mechanism underlying many antibody drugs
  • Describing a bispecific antibody approach to harness phagocytic receptor CLEC5A in driving Fcγ receptorindependent phagocytosis
  • Establishing effectiveness of this approach by constructing bispecific antibodies that simultaneously target CLEC5A and live B cells

1:45 pm Kick-Starting Tumor Specific T Cell Cross-Priming Using Neo-X-Prime Bispecific Antibodies Targeting CD40


  • Using CD40 as a target molecule and highly expressed tumor antigens as the second target molecule
  • Generating an effective T cell response to the tumor antigen using Neo-X-Prime

2:15 pm Expanding the Therapeutic Window for Immune- Engaging Multi-Specifics Through Conditional Activation & Co-Stimulation

  • David Poon Vice President – Business Development & Alliance Management, Zymeworks


  • ProTECT™ platform to engineer conditionally-active antibodies combined with checkpoint modulation to enhance therapeutic windows
  • Mechanistic validation and in vivo demonstration of enhanced potency for a proof-of-concept CD3-redirecting multispecific with PD-L1 modulation

2:45 pm Retrospective Look at Translational Considerations & FIH Dosing Approaches for T-cell Redirectors

  • Prathap Shastri Scientific Director, DMPK, Preclinical Sciences and Translational Safety, Johnson & Johnson


  • Review learnings from clinical programs and how it influences translational considerations for future pipeline
  • Discuss various approaches for FIH dosing approaches and retrospective analysis based on learnings from clinical studies
  • Delving into MABEL strategy for multispecifics and combination trials

Product Design

1:15 pm ISB 1442, a First-in-Class 2+1 Fc Engineered Biparatopic Bispecific BEAT® 2.0 antibody targeting CD38 and CD47


  • Understanding the BEAT platform: versatility and developability
  • Taking a deep dive into Fc engineering of BEAT 2.0
  • Analyzing ISB 1442 first-in-class Fc engineered biparatopic 2+1

1:45 pm Correlating Multispecific Structures to their Functions for a Holistic Overview of Product Design


  • Discussing effects of designing a bispecific, and the choice of binding arms
  • Uncovering the profound effects this has on the activity and synergy of the antibody

2:15 pm Exploring the Consequences of Codon Optimization on Therapeutic Sequences

  • Chava Kimchi-Sarfaty Deputy Associate Director - Research Office of Tissue & Advanced Therapies, CBER, FDA


  • Focusing on the types of codon optimization and considerations
  • Deep dive into understanding how codon optimization of therapeutic sequences may affect the proteins’ characteristics
  • Uncovering examples of codon optimizations that affect protein conformations, cell growth, and translation rates

2:45 pm Rational Engineering of an Erythropoietin Fusion Protein to Treat Hypoxia”

  • Jeffrey Way Lecturer - Department of Systems Biology, Harvard Medical School


  • Targeting multiple receptor subclasses with one protein
  • Minimizing side effects through tissue targeting and quantitative/spatial optimization
  • Enhanced pharmacokinetics through red blood cell binding

3:15 pm
Afternoon Break & Networking

Extrapolating Clinical Trial Design Learnings for the Best Shot at Success

3:45 pm Roundtable Discussion – Clinical Updates from Industry Pioneers in the Multispecific Field


  • Understanding how the projects progressed and what is effective in the clinic
  • Approaching clinical trial design for unapproved agents being tested simultaneously

4:15 pm Chair’s Closing Remarks

4:30 pm Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda allowing you to connect with your peers in a relaxed atmosphere and continue to develop new and existing relationships. During this session, scientific posters will be presented on the cutting-edge advances of multispecifics